Tanacetum parthenium

Tanacetum parthenium, commonly called feverfew, contains parthenolide as its primary bioactive sesquiterpene lactone, which inhibits platelet aggregation and NF-κB-mediated inflammatory signaling. It is clinically studied for migraine prophylaxis, reducing attack frequency through inhibition of prostaglandin synthesis and serotonin release from platelets.

Origin & History

Tanacetum parthenium, commonly known as feverfew, is a perennial herb native to the Balkan Peninsula and southern Europe, now widely naturalized in North America. The aerial parts (leaves and flowers) are processed via supercritical CO2 extraction or ethanol extraction to produce standardized preparations like MIG-99.

Historical & Cultural Context

Feverfew has been used in European folk medicine for centuries to treat migraines, menstrual pain, toothaches, rheumatism, and fever, typically as leaf infusions. British herbalism and Mediterranean folk practices documented its use well before modern clinical trials began in the 1980s.

Health Benefits

• Reduces migraine frequency by up to 1.8 attacks per month in high-frequency sufferers (≥4 baseline attacks) based on RCT evidence (PMID: 12230594)
• Decreases tension-type headache frequency from 11.97 to 5.13 attacks per 28 days in pediatric populations when combined with other nutraceuticals (PMID: 30871574)
• Reduces migraine pain intensity by 62.6% and duration by 76.2% when combined with Salix alba in open-label studies (PMID: 17163262)
• Provides anti-inflammatory effects through NF-κB inhibition and prostaglandin synthesis blockade based on mechanistic studies
• Shows potential for migraine prophylaxis supported by systematic review and meta-analysis of multiple RCTs (PMID: 41422534)

How It Works

Parthenolide, the primary bioactive compound in Tanacetum parthenium, covalently modifies the p65 subunit of NF-κB, blocking transcription of pro-inflammatory cytokines including TNF-α and IL-1β. It also inhibits phospholipase A2, reducing arachidonic acid release and downstream prostaglandin and thromboxane synthesis. Additionally, parthenolide inhibits serotonin release from platelets and suppresses smooth muscle spasms in cerebral vasculature, directly addressing core mechanisms implicated in migraine pathophysiology.

Scientific Research

Clinical evidence includes multiple RCTs with mixed results, including a 147-patient adaptive design trial showing benefit only in high-frequency migraine subgroups (PMID: 12230594), and a pediatric observational study (n=91) demonstrating significant headache reduction (PMID: 30871574). A recent systematic review and meta-analysis confirms potential for migraine frequency and severity reduction (PMID: 41422534).

Clinical Summary

A double-blind RCT (PMID: 12230594) demonstrated that standardized feverfew extract reduced migraine frequency by approximately 1.8 attacks per month compared to placebo in patients experiencing four or more baseline monthly attacks, representing clinically meaningful prophylactic efficacy. In pediatric populations, a nutraceutical combination including feverfew reduced tension-type headache frequency from 11.97 to 5.13 attacks per 28 days, though the multi-ingredient design limits attribution to feverfew alone. Evidence is strongest for migraine prevention rather than acute treatment, and most positive trials use standardized extracts containing at least 0.2% parthenolide. Overall evidence quality is moderate, with some trials limited by small sample sizes and short durations of six to twelve weeks.

Nutritional Profile

Tanacetum parthenium (feverfew) is not consumed as a food for macronutrient value; it is used as an herbal medicine, and its nutritional relevance lies entirely in its bioactive phytochemical profile. Key compounds include: • **Sesquiterpene lactones** – Parthenolide is the principal bioactive compound, typically present at 0.2–1.0% of leaf dry weight (standardized extracts often guarantee ≥0.2–0.7% parthenolide). Parthenolide inhibits NF-κB activation, suppresses pro-inflammatory prostaglandin synthesis, and modulates serotonin release from platelets. Bioavailability of parthenolide is moderate orally but subject to first-pass metabolism; lipophilic formulations and CO₂-extracted preparations may improve absorption. Other sesquiterpene lactones include canin, artecanin, secotanapartholide A and B, and 3β-hydroxyparthenolide. • **Flavonoids** – Includes tanetin (a lipophilic flavonol, ~0.5–1.0% dry weight), apigenin, luteolin, chrysoeriol, and santin. These contribute anti-inflammatory and antioxidant activity. Apigenin and luteolin have moderate oral bioavailability (~5–10%) due to extensive glucuronidation. • **Volatile oils (essential oil)** – 0.02–0.07% of fresh herb; composed primarily of camphor (~40–55% of essential oil), camphene (~10–15%), p-cymene, bornyl acetate, β-farnesene, germacrene D, and chrysanthenyl acetate. These contribute to the herb's characteristic aroma and mild spasmolytic effects. • **Melatonin** – Feverfew leaves contain relatively high phytomelatonin levels (~2.45 µg/g dry weight), which may contribute to its headache-modulating properties. • **Phenolic acids** – Caffeic acid, chlorogenic acid, and 3,5-dicaffeoylquinic acid are present in minor quantities, providing antioxidant activity (ORAC-relevant). • **Tannins** – Present in trace amounts (~1–3% dry weight), contributing astringent properties. • **Micronutrients** – Not a significant dietary source; trace amounts of iron, manganese, zinc, magnesium, potassium, and vitamins A and C are present in fresh leaf tissue but at levels too low to be nutritionally meaningful given typical dosing (50–150 mg dried leaf/day). • **Fiber and macronutrients** – Dried leaf contains roughly 8–12% crude protein, 3–5% lipids, 15–20% crude fiber, and ~50% carbohydrate on a dry weight basis, but these are irrelevant at medicinal doses. • **Bioavailability notes** – Parthenolide stability is a major concern: it degrades significantly during drying and storage, especially in powdered preparations. Fresh or freeze-dried leaf preparations and supercritical CO₂ extracts retain higher parthenolide content. Enteric-coated capsules may reduce gastric degradation. MiGreenol® (CO₂ extract) and standardized ethanol extracts (e.g., MIG-99, stable parthenolide content ~0.5%) have demonstrated improved and more consistent oral bioavailability in clinical trials. Co-administration with lipids may enhance parthenolide absorption due to its lipophilic nature (LogP ~1.7).

Preparation & Dosage

Clinically studied doses include: MIG-99 standardized CO2 extract at 6.25 mg three times daily (18.75 mg/day total) for high-frequency migraine; leaf extract 300 mg twice daily (600 mg/day), often combined with Salix alba; fixed-dose nutraceutical combinations once daily. Standardization typically targets 0.2-0.8% parthenolide content. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Salix alba, CoQ10, Riboflavin, Magnesium, Andrographis paniculata

Safety & Interactions

The most commonly reported adverse effects are mouth ulcers and oral inflammation, occurring in approximately 10–18% of users who chew fresh leaves, and GI disturbances such as nausea and abdominal pain. Abrupt discontinuation after prolonged use can cause 'post-feverfew syndrome,' characterized by rebound headaches, anxiety, and muscle stiffness. Tanacetum parthenium inhibits platelet aggregation and should be used cautiously alongside anticoagulants such as warfarin or antiplatelet agents like aspirin and clopidogrel due to additive bleeding risk. It is contraindicated during pregnancy due to uterotonic properties of parthenolide, which may stimulate uterine contractions, and is not recommended during lactation.